525 Rec'd PCT/PTC 2 6

TRADEM Pase type a plus sign	(+) inside this box +	Approv	PTO/SB/21 (08-00) /ved for use through 10/31/2002. OMB 0651-0031						
		U.S. Patent and Tradem	ark Office: U.S. DEPARTMENT OF COMMERCE on unless it displays a valid OMB control number.						
		Application Number	09/673,958						
TRANSMITTAL		Filing Date	August 13, 2001						
FORM		First Named Inventor	M. NANBA A E						
(to be used for all correspondence after initial filing)		Group Art Unit	1645						
		Examiner Name	tba $\frac{30}{60}$ $\frac{7}{2}$						
Total Number of Pag	es in This Submission 7	Attorney Docket Number	2519 US0P 🕺 🦰 🦷						
	ENCL	OSURES (check	all that apply)						
Fee Transmittal Form		nent Papers Application)	After Allowance Communication to Group						
Fee Attached	Drawing	p(s)	Appeal Communication to Board of Appeals and Interferences						
Amendment / Reply	Licensin	ng-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)						
After Final	Petition		Proprietary Information						
Affidavits/declarat	ion(s) Provisio	to Convert to a enal Application	Status Letter						
Extension of Time Reque	est Change Address		Other Enclosure(s) (please identify below):						
Express Abandonment R	Request	al Disclaimer et for Refund	Return Postcard. Certificate of Express Mailing						
Information Disclosure St	tatement	mber of CD(s)	Request to Correct Filing Receipt Copy of Filing Receipt						
Certified Copy of Priority Document(s)		, ,	r is harshy sytherized to						
Response to Missing Par	rts/		er is hereby authorized to onal fees which may be						
Incomplete Application		•	any overpayment to						
Response to Missi under 37 CFR 1.52		Deposit Account 5							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
Firm									
or Mark Chao Ph.D., JD, Reg. No 37,293 Individual name									
Signature 2/1///									
Date 6/16/52									
CERTIFICATE OF MAILING									
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first of the sufficient postag									
Typed or printed name Gail L. Winokur									
Signature Fail of.		okur Date	6/26/02						

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EV 082675-418 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

BAS plication No.:

09/673,958

Filed:

August 13, 2001

1st Inventor:

M. NANBA

For:

Human Derived Immortalized Liver Cell Line

Atty. Dkt. No.

2519 US0P

Art Unit:

1645

tba

Examiner:

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 082675418 US

DATE IN:

June 26, 2002

RECEIVED

JUL 1 7 2002

Itemized Papers/Items:

TECH CENTER 1600/2900

- 1. This certificate and a Return Receipt Postcard (2 pgs.)
- 2. Transmittal Form (1 pg. X 2)
- 3. Request to Correct Filing Receipt, and copy of Filing Receipt (3 pgs.)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231.

on this date, 6/26/02

Dated: 6/26/02

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA



Application No.:

09/673,958

Filed:

August 13, 2001

1st Inventor:

M. NANBA

For:

Human Derived Immortalized Liver Cell Line

Atty. Dkt. No.

2519 US0P

Art Unit:

1645

Examiner:

tba

Allowed:

Batch:

Paper No.:

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, D.C. 20231

Sir:

v

Applicants request that a corrected Filing Receipt be issued for the above-identified case correcting the misspelling of inventor Nanba's first name, and correcting the typographical error in the title of the invention.

Please correct the spelling of inventor Nanba's first name to read as follows:

--Masayoshi Nanba--

Please rewrite the title of the invention to read as follows:

-- HUMAN DERIVED IMMORTALIZED LIVER CELL LINE --

A copy of the Filing Receipt is enclosed showing the correction.

If there are any questions, please call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: 6/26/02

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA



23115

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
Washington, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/673,958	08/13/2001	1645	1230	2519US0P	5	11	1

CONFIRMATION NO. 8993

REPLACEMENT FILING RECEIPT

OC000000008329278

INTELLECTUAL PROPERTY DEPARTMENT 475 HALF DAY ROAD

SUITE 500 LINCOLNSHIRE, IL 60069

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC

Mar

Date Mailed: 06/21/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) -- Masayoshi --

Nasayeshi Nanba, Okayama, JAPAN; Kenichi Fukaya, Katsuyama-shi, JAPAN; Satoru Asahi, Osaka, JAPAN; Sumie Yoshitomi, Osaka, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/02224 04/27/1999

Foreign Applications

JAPAN 10-119394 04/28/1998


Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

Human deriven immortalized liver cell line --derived--



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).